Your browser is no longer supported. Please, upgrade your browser.
Settings
VNDA Vanda Pharmaceuticals Inc. daily Stock Chart
VNDA [NASD]
Vanda Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-0.11 Insider Own3.50% Shs Outstand52.25M Perf Week6.13%
Market Cap995.36M Forward P/E55.38 EPS next Y0.34 Insider Trans-14.15% Shs Float50.73M Perf Month12.06%
Income-4.90M PEG- EPS next Q-0.19 Inst Own93.30% Short Float4.39% Perf Quarter12.72%
Sales171.30M P/S5.81 EPS this Y16.00% Inst Trans17.67% Short Ratio3.98 Perf Half Y32.75%
Book/sh5.20 P/B3.66 EPS next Y245.00% ROA-2.10% Target Price20.67 Perf Year35.59%
Cash/sh4.76 P/C4.00 EPS next 5Y15.70% ROE-3.10% 52W Range11.90 - 20.40 Perf YTD25.33%
Dividend- P/FCF269.02 EPS past 5Y19.30% ROI-13.00% 52W High-6.62% Beta0.87
Dividend %- Quick Ratio3.90 Sales past 5Y38.20% Gross Margin89.30% 52W Low60.08% ATR0.47
Employees273 Current Ratio3.90 Sales Q/Q16.60% Oper. Margin-3.80% RSI (14)76.93 Volatility3.07% 2.58%
OptionableYes Debt/Eq0.00 EPS Q/Q136.90% Profit Margin-2.80% Rel Volume0.71 Prev Close19.00
ShortableYes LT Debt/Eq0.00 EarningsMay 02 AMC Payout- Avg Volume559.79K Price19.05
Recom2.00 SMA207.57% SMA5016.65% SMA20017.98% Volume396,266 Change0.26%
May-23-18Initiated Citigroup Buy $26
Jan-19-18Initiated Seaport Global Securities Buy $20
Sep-14-17Reiterated Piper Jaffray Overweight $23 → $26
Jun-27-17Resumed Piper Jaffray Overweight $23
May-26-17Initiated H.C. Wainwright Buy $18
Apr-12-17Initiated Oppenheimer Outperform $21
Nov-09-16Initiated Aegis Capital Buy $24
Oct-06-16Resumed Jefferies Buy
Jan-09-15Initiated Canaccord Genuity Buy $22
Mar-10-10Initiated Hapoalim Outperform $23
Feb-17-10Reiterated Jefferies & Co Buy $22 → $20
Dec-09-09Initiated Jefferies & Co Buy $22
Jul-29-08Downgrade JP Morgan Overweight → Neutral
Jul-29-08Downgrade Banc of America Sec Buy → Neutral
Jul-28-08Downgrade Caris & Company Buy → Above Average $22 → $3
May-02-08Initiated Caris & Company Buy $22
Nov-09-07Reiterated Friedman Billings Outperform $31 → $16
Nov-01-07Reiterated Friedman Billings Outperform $37 → $31
Sep-10-07Initiated Banc of America Sec Buy
May-08-07Initiated Citigroup Hold
Jun-08-18 07:00AM  TG Therapeutics and Three Additional Stocks Under Scanner in the Biotech Space ACCESSWIRE
Jun-01-18 12:00PM  Vanda Pharmaceuticals Announces Participation at June 2018 Investor Conferences PR Newswire
May-24-18 03:00AM  Stocks Generating Improved Relative Strength: Vanda Pharmaceuticals Investor's Business Daily
May-23-18 08:00AM  HETLIOZ® (tasimelteon) Effective in Treating Jet Lag during Transatlantic Travel PR Newswire
May-16-18 11:52AM  Edited Transcript of VNDA earnings conference call or presentation 2-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-10-18 08:00AM  Investor Expectations to Drive Momentum within Plains Group Holdings, EnteroMedics, Vanda Pharmaceuticals, Cinemark, EPR Properties, and The Estee Lauder Companies Discovering Underlying Factors of Influence GlobeNewswire
May-07-18 09:00AM  Vanda Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference PR Newswire
May-02-18 05:43PM  Vanda: 1Q Earnings Snapshot Associated Press
04:01PM  Vanda Pharmaceuticals Reports First Quarter 2018 Financial Results PR Newswire
Apr-30-18 08:50AM  AVEO Pharmaceuticals (AVEO) Q1 Earnings: What's in Store? Zacks
Apr-27-18 07:44AM  Zacks.com highlights: Illumina, Alarm.com Holdings, Copart and Vanda Pharmaceuticals Zacks
Apr-26-18 12:35PM  4 Top Efficient Stocks to Buy for Stellar Returns InvestorPlace
10:20AM  4 Top Efficient Stocks to Buy for Stellar Returns Zacks
Apr-24-18 08:06AM  Vanda Pharmaceuticals Inc. (VNDA) Sees Hammer Chart Pattern: Time to Buy? Zacks
Apr-18-18 04:30PM  Vanda Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 2, 2018 PR Newswire
Apr-13-18 12:00PM  Vanda Wins Appeal Case on Fanapt® PR Newswire
Apr-09-18 04:01PM  Vanda to Present Tradipitant Scientific Posters at the 10th Georg Rajka International Symposium of Atopic Dermatitis PR Newswire -5.52%
Mar-16-18 08:30AM  Vanda Pharmaceuticals Inc (NASDAQ:VNDA) Investors Are Paying Above The Intrinsic Value Simply Wall St. -5.28%
Mar-15-18 07:46PM  Vanda Pharmaceuticals Inc. Prices Public Offering of Common Stock PR Newswire -11.04%
Mar-14-18 04:01PM  Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock PR Newswire
Mar-06-18 04:30PM  Vanda Pharmaceuticals Announces Participation at March 2018 Investor Conferences PR Newswire
Mar-05-18 09:24PM  A drug for jet lag? A D.C. biotech says it just got a lot closer. American City Business Journals
07:00AM  HETLIOZ® (tasimelteon) Demonstrates Efficacy to Treat Jet Lag Disorder in an 8 Hour Phase Advance Clinical Study PR Newswire
Feb-26-18 07:10AM  Wired News Kadmon Presented Updated Positive Results from Phase-2 Study of KD025 in Chronic Graft-Versus-Host Disease at BMT Tandem Meetings ACCESSWIRE
Feb-16-18 03:08AM  Edited Transcript of VNDA earnings conference call or presentation 14-Feb-18 9:30pm GMT Thomson Reuters StreetEvents
Feb-14-18 04:01PM  Vanda Pharmaceuticals Reports Fourth Quarter 2017 and Full Year 2017 Financial Results PR Newswire
12:10PM  Vanda Pharmaceuticals Inc. to Host Earnings Call ACCESSWIRE
Feb-13-18 08:10AM  Detailed Research: Economic Perspectives on Omega Healthcare Investors, Vanda Pharmaceuticals, Acushnet, Prospect Capital, Intercontinental Exchange, and Glaukos What Drives Growth in Today's Competitive Landscape GlobeNewswire
Jan-30-18 04:30PM  Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results on February 14, 2018 PR Newswire
Jan-07-18 09:00AM  Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2017 Revenue Results and 2018 Guidance PR Newswire
Dec-26-17 12:18PM  ETFs with exposure to Vanda Pharmaceuticals, Inc. : December 26, 2017 Capital Cube
Dec-22-17 09:26AM  Vanda Pharmaceuticals, Inc. :VNDA-US: Earnings Analysis: Q3, 2017 By the Numbers : December 22, 2017 Capital Cube
Dec-20-17 07:22AM  Vanda Pharmaceuticals, Inc. is trading above its 50 day moving average : VNDA-US : December 20, 2017 Capital Cube
Dec-12-17 11:37AM  Edited Transcript of VNDA earnings conference call or presentation 7-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
Nov-27-17 07:30AM  Research Report Identifies Walker & Dunlop, Vanda Pharmaceuticals, Acushnet, SS&C Technologies, ManpowerGroup, and Glaukos with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Nov-13-17 09:00AM  Vanda Pharmaceuticals Announces Participation at November 2017 Investor Conferences PR Newswire
Nov-10-17 04:05PM  Vanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum for the Treatment of Schizophrenia PR Newswire
Nov-07-17 05:14PM  Vanda reports 3Q loss Associated Press -5.08%
04:01PM  Vanda Pharmaceuticals Reports Third Quarter 2017 Financial Results PR Newswire
12:30PM  Vanda Pharmaceuticals Inc. to Host Earnings Call ACCESSWIRE
Oct-27-17 11:20AM  ETFs with exposure to Vanda Pharmaceuticals, Inc. : October 27, 2017 Capital Cube
Oct-24-17 05:00PM  Vanda Pharmaceuticals to Announce Third Quarter 2017 Financial Results on November 7, 2017 PR Newswire
Oct-17-17 10:03AM  ETFs with exposure to Vanda Pharmaceuticals, Inc. : October 17, 2017 Capital Cube
Oct-10-17 06:15PM  Vanda Pharmaceuticals Announces Participation at the Oppenheimer Specialty Pharma Summit Conference PR Newswire
08:25AM  Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : October 10, 2017 Capital Cube
Oct-02-17 11:10AM  ETFs with exposure to Vanda Pharmaceuticals, Inc. : October 2, 2017 Capital Cube
09:15AM  Vanda to Present Tradipitant Phase II Atopic Dermatitis Data at World Congress of Itch PR Newswire
Sep-29-17 01:00PM  Vanda to Present Scientific Posters at World Sleep 2017 PR Newswire
09:00AM  Vanda Pharmaceuticals, Inc. :VNDA-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017 Capital Cube
Sep-19-17 07:31AM  These 3 Biotech Stocks Just Hit 52-Week Highs: Are They Buys? Motley Fool
Sep-14-17 10:25AM  Is It Too Late To Buy Vanda Pharmaceuticals Inc (VNDA)? Simply Wall St.
10:06AM  Summit Therapeutics Stock Gets Smoked After IPO Pricing TheStreet.com
Sep-13-17 04:49PM  Vanda Pharma shares decline as goal of itch drug study not reached MarketWatch
04:04PM  Vanda's Tradipitant Improves Itch and Disease Severity in Patients with Atopic Dermatitis PR Newswire
Sep-11-17 05:00PM  Vanda Pharmaceuticals Announces Participation at September 2017 Investor Conferences PR Newswire
Sep-06-17 05:00PM  Vanda Pharmaceuticals Announces Participation at the Citi 12th Annual Biotech Conference PR Newswire
Sep-01-17 09:56AM  Edited Transcript of VNDA earnings conference call or presentation 2-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-29-17 08:46AM  Looking for a Top Momentum Stock? 3 Reasons Why Vanda Pharmaceuticals (VNDA) is a Great Choice Zacks
Aug-28-17 11:01AM  Zacks.com featured highlights Sanderson Farm, Heska Corp, Vanda Pharmaceuticals Lantheus and NVR Zacks
Aug-25-17 10:43AM  5 Efficient Stocks to Buy for a Healthy Portfolio Zacks
Aug-23-17 08:55AM  Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : August 23, 2017 Capital Cube
Aug-21-17 07:52PM  Vanda Pharmaceuticals, Inc. Value Analysis (NASDAQ:VNDA) : August 21, 2017 Capital Cube
Aug-16-17 08:30AM  Strength Seen in Vascular Biogenics (VBLT): Stock Jumps 5.3% Zacks
Aug-09-17 09:20AM  Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : August 9, 2017 Capital Cube
Aug-04-17 04:29PM  Vanda Pharmaceuticals preps for jet lag study results later this year American City Business Journals
Aug-02-17 05:41PM  Vanda reports 2Q loss Associated Press
04:01PM  Vanda Pharmaceuticals Reports Second Quarter 2017 Financial Results PR Newswire
10:10AM  Investor Network: Vanda Pharmaceuticals Inc. to Host Earnings Call ACCESSWIRE
Jul-21-17 07:00AM  Vanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum for the Treatment of Schizophrenia PR Newswire
Jul-17-17 09:00AM  Vanda Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 2, 2017 PR Newswire
Jul-14-17 09:30AM  The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals Zacks
Jul-13-17 02:31PM  5 Drug Stocks Well Poised to Beat Q2 Earnings Estimates Zacks
Jun-21-17 08:30AM  Vanda Pharmaceuticals (VNDA) Worth a Look: Stock Jumps 8% Zacks
08:06AM  Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : June 21, 2017 Capital Cube
Jun-05-17 05:00PM  Vanda Pharmaceuticals Announces Participation at June 2017 Investor Conferences PR Newswire
May-30-17 02:35PM  Edited Transcript of VNDA earnings conference call or presentation 2-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-22-17 08:37AM  Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : May 22, 2017 Capital Cube
May-09-17 08:54AM  Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : May 9, 2017 Capital Cube
May-05-17 04:41PM  ETFs with exposure to Vanda Pharmaceuticals, Inc. : May 5, 2017 Capital Cube
12:21PM  Edited Transcript of VNDA earnings conference call or presentation 2-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-04-17 05:09PM  Vanda Pharmaceuticals expands into cystic fibrosis, blood cancer American City Business Journals
10:20AM  Vanda Pharmaceuticals, Inc. :VNDA-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017 Capital Cube
May-02-17 06:10PM  Vanda reports 1Q loss Associated Press
04:01PM  Vanda Pharmaceuticals Reports First Quarter 2017 Financial Results PR Newswire
08:35AM  Investor Network: Vanda Pharmaceuticals Inc. to Host Earnings Call Accesswire
May-01-17 05:45PM  Vanda Pharmaceuticals to Present at the Deutsche Bank 42nd Annual Health Care Conference PR Newswire
Apr-20-17 03:24PM  Vanda Pharmaceuticals, Inc. Value Analysis (NASDAQ:VNDA) : April 20, 2017 Capital Cube
Apr-19-17 08:14AM  Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : April 19, 2017 Capital Cube
Apr-13-17 04:45PM  Vanda Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 2, 2017 PR Newswire
Mar-31-17 08:33AM  Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : March 31, 2017 Capital Cube
08:33AM  Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : March 31, 2017
Mar-29-17 05:40PM  Vanda and UCSF Announce License Agreement for CFTR Activators and Inhibitors PR Newswire
Mar-21-17 08:16AM  Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : March 21, 2017
Mar-13-17 05:23PM  VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers
Mar-07-17 07:17AM  Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : March 7, 2017 Capital Cube
07:17AM  Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : March 7, 2017
Mar-06-17 04:07PM  VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers
04:05PM  Vanda Pharmaceuticals Announces Participation at March 2017 Investor Conferences PR Newswire
Feb-22-17 01:04PM  VANDA PHARMACEUTICALS INC. Financials
11:22AM  Vanda Pharmaceuticals, Inc. :VNDA-US: Earnings Analysis: Q4, 2016 By the Numbers : February 22, 2017 Capital Cube
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its products also include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; VTR-297, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. In addition, the company is developing cystic fibrosis transmembrane conductance regulator activators and inhibitors. It markets its products in the United States, Canada, Europe, Israel, and Mexico. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Watkins ThomasDirectorMay 03Option Exercise4.9815,00074,70020,000May 04 04:06 PM
DUGAN RICHARD WDirectorMar 19Option Exercise4.9815,00074,70025,770Mar 20 05:02 PM
Polymeropoulos Mihael HristosPresident and CEOMar 01Sale18.7260,9661,141,0031,182,872Mar 02 05:36 PM
Kelly James PatrickEVP & Chief Financial OfficerMar 01Sale18.728,532159,712199,534Mar 02 05:34 PM
Birznieks GuntherSVP, Business DevelopmentMar 01Sale18.728,525159,605139,841Mar 02 05:32 PM
Gulino Richard L.SVP, General Counsel & Sec.Mar 01Sale18.713,66068,473115,073Mar 02 05:33 PM
Polymeropoulos Mihael HristosPresident and CEOJan 02Option Exercise5.76250,0001,440,0001,281,848Jan 04 05:13 PM
Polymeropoulos Mihael HristosPresident and CEOJan 02Sale15.30191,7602,933,1271,111,623Jan 04 05:13 PM
Kelly James PatrickEVP & Chief Financial OfficerJan 02Sale15.359,155140,494168,066Jan 04 05:12 PM
Gulino Richard L.SVP, General Counsel & Sec.Jan 02Sale15.2010,367157,56588,733Jan 04 05:11 PM
Birznieks GuntherSVP, Business DevelopmentJan 02Sale15.268,568130,777118,366Jan 04 05:09 PM